retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Receptor Agonists Dual and Triple Gut Peptide

10.1053/j.ajkd.2024.11.013 14 ChengC

All analyses were conducted on previously published studies and publicly available data

This choice, which was based upon what was learned from recent global GLP-1 diabetes and obesity drug shortages, guarantees an ongoing and predictable supply of medicine to the Chinese patients, increases loyalty for the brand, and gives shareholders dependable revenue streams that are not impacted by geopolitical instability

Understanding the intricate relationship between payer control, channel distribution, and volume uptake can provide invaluable insights, not just within the diabetes and anti-obesity medicines (AOM) markets

doi: 10.1038/npp.2014.74 32 AlhadeffALRupprechtLEHayesMR